Piramal Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Piramal Pharma Ltd rose 3.8% today to trade at Rs 229.65. The BSE Healthcare index is up 0.47% to quote at 41671.82. The index is up 3.91 % over last one month. Among the other constituents of the index, Kopran Ltd increased 2.86% and Ajanta Pharma Ltd added 2.76% on the day. The BSE Healthcare index went up 22.24 % over last one year compared to the 4.89% surge in benchmark SENSEX.

Piramal Pharma Ltd has added 14.57% over last one month compared to 3.91% gain in BSE Healthcare index and 0.34% rise in the SENSEX. On the BSE, 1.17 lakh shares were traded in the counter so far compared with average daily volumes of 5.79 lakh shares in the past one month. The stock hit a record high of Rs 307.85 on 06 Nov 2024. The stock hit a 52-week low of Rs 117.3 on 26 Mar 2024.

Powered by Capital Market - Live News

In a regulatory filing made after market hours yesterday, the pharmaceutical company stated that the US FDA had conducted a General GMP inspection at its Turbhe facility from 11th February 2025 to 17th February 2025.

On conclusion of the inspection, a Form-483 was issued with 6 observations. “Observations are largely around improvement of procedures and practices and not related to data integrity.

The company is preparing a detailed response to said observations, which will be submitted to agency within stipulated timelines,” Piramal Pharma said in a statement.

Piramal Pharma (PPL) is a part of the Piramal group of companies. The pharmaceutical product portfolio of the company can be categorised into contract development and manufacturing organisations (CDMO), complex hospital generics (critical care), and consumer healthcare (OTC).

Powered by Capital Market - Live News

Profit before tax stood at Rs 66.80 crore in the December 2024 quarter, registering a growth of 245.04% on YoY basis.

During the quarter, EBITDA grew 6% YoY to Rs 350 crore and EBITDA margin improved to 16% as against 17% posted in Q3 FY24.

On nine-month basis, the firm’s reported consolidated net loss of Rs 62.37 crore in 9M FY25 as against net loss of Rs 83.45 crore in 9M FY24.

Revenue from operations grew 13.85% YoY to Rs 6,397.11 crore during the nine period ended on 31 December 2024, primarily driven by high-teen growth in the CDMO business.

EBITDA grew by 20% YoY to Rs 977 crore for 9M FY25, supported by operating leverage, cost optimization initiatives and superior revenue mix.

The company's revenue from contract development and manufacturing organization (CDMO) was at Rs 3,659 crore (up 18% YoY), complex hospital generics (CHG) stood at Rs 1,928 crore (up 8% YoY) and India consumer healthcare (ICH) came in at Rs 819 crore (up 10% YoY) during the period under review.

Nandini Piramal, chairperson of Piramal Pharma, said, “FY25 so far has been a steady year for the Company with revenue growth of 14% and EBITDA growing at 20%. Our CDMO business continues to deliver robust performance with 18% revenue growth along with EBITDA margin improvement in 9MFY25. This performance was largely led by innovation related work.

Our CHG business registered an early-teen revenue growth during the quarter on the back of strong volume growth in our Inhalation Anesthesia portfolio. In our ICH business, power brands continue to register about 19% growth.

The quarter also marked a significant milestone in our journey towards sustainable manufacturing with the conversion of coal-fired steam boiler at our Digwal facility to operate on biomass briquettes. This will significantly reduce our GHG emissions - underscoring our unwavering commitment towards the planet.”

Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products.

The scrip added 1.67% to currently trade at Rs 222.60 on the BSE.

Powered by Capital Market - Live News

In a regulatory filing made after market hours yesterday, the pharmaceutical company stated that the US FDA had conducted a General GMP inspection at its Turbhe facility from 11th February 2025 to 17th February 2025.

On conclusion of the inspection, a Form-483 was issued with 6 observations. “Observations are largely around improvement of procedures and practices and not related to data integrity.

The company is preparing a detailed response to said observations, which will be submitted to agency within stipulated timelines,” Piramal Pharma said in a statement.

Piramal Pharma (PPL) is a part of the Piramal group of companies. The pharmaceutical product portfolio of the company can be categorised into contract development and manufacturing organisations (CDMO), complex hospital generics (critical care), and consumer healthcare (OTC).

Powered by Capital Market - Live News

Profit before tax stood at Rs 66.80 crore in the December 2024 quarter, registering a growth of 245.04% on YoY basis.

During the quarter, EBITDA grew 6% YoY to Rs 350 crore and EBITDA margin improved to 16% as against 17% posted in Q3 FY24.

On nine-month basis, the firm’s reported consolidated net loss of Rs 62.37 crore in 9M FY25 as against net loss of Rs 83.45 crore in 9M FY24.

Revenue from operations grew 13.85% YoY to Rs 6,397.11 crore during the nine period ended on 31 December 2024, primarily driven by high-teen growth in the CDMO business.

EBITDA grew by 20% YoY to Rs 977 crore for 9M FY25, supported by operating leverage, cost optimization initiatives and superior revenue mix.

The company's revenue from contract development and manufacturing organization (CDMO) was at Rs 3,659 crore (up 18% YoY), complex hospital generics (CHG) stood at Rs 1,928 crore (up 8% YoY) and India consumer healthcare (ICH) came in at Rs 819 crore (up 10% YoY) during the period under review.

Nandini Piramal, chairperson of Piramal Pharma, said, “FY25 so far has been a steady year for the Company with revenue growth of 14% and EBITDA growing at 20%. Our CDMO business continues to deliver robust performance with 18% revenue growth along with EBITDA margin improvement in 9MFY25. This performance was largely led by innovation related work.

Our CHG business registered an early-teen revenue growth during the quarter on the back of strong volume growth in our Inhalation Anesthesia portfolio. In our ICH business, power brands continue to register about 19% growth.

The quarter also marked a significant milestone in our journey towards sustainable manufacturing with the conversion of coal-fired steam boiler at our Digwal facility to operate on biomass briquettes. This will significantly reduce our GHG emissions - underscoring our unwavering commitment towards the planet.”

Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products.

The scrip added 1.67% to currently trade at Rs 222.60 on the BSE.

Powered by Capital Market - Live News

Net profit of Piramal Pharma declined 63.60% to Rs 3.68 crore in the quarter ended December 2024 as against Rs 10.11 crore during the previous quarter ended December 2023. Sales rose 12.54% to Rs 2204.22 crore in the quarter ended December 2024 as against Rs 1958.57 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Piramal Pharma Ltd rose 3.8% today to trade at Rs 229.65. The BSE Healthcare index is up 0.47% to quote at 41671.82. The index is up 3.91 % over last one month. Among the other constituents of the index, Kopran Ltd increased 2.86% and Ajanta Pharma Ltd added 2.76% on the day. The BSE Healthcare index went up 22.24 % over last one year compared to the 4.89% surge in benchmark SENSEX.

Piramal Pharma Ltd has added 14.57% over last one month compared to 3.91% gain in BSE Healthcare index and 0.34% rise in the SENSEX. On the BSE, 1.17 lakh shares were traded in the counter so far compared with average daily volumes of 5.79 lakh shares in the past one month. The stock hit a record high of Rs 307.85 on 06 Nov 2024. The stock hit a 52-week low of Rs 117.3 on 26 Mar 2024.

Powered by Capital Market - Live News

In a regulatory filing made after market hours yesterday, the pharmaceutical company stated that the US FDA had conducted a General GMP inspection at its Turbhe facility from 11th February 2025 to 17th February 2025.

On conclusion of the inspection, a Form-483 was issued with 6 observations. “Observations are largely around improvement of procedures and practices and not related to data integrity.

The company is preparing a detailed response to said observations, which will be submitted to agency within stipulated timelines,” Piramal Pharma said in a statement.

Piramal Pharma (PPL) is a part of the Piramal group of companies. The pharmaceutical product portfolio of the company can be categorised into contract development and manufacturing organisations (CDMO), complex hospital generics (critical care), and consumer healthcare (OTC).

Powered by Capital Market - Live News

Profit before tax stood at Rs 66.80 crore in the December 2024 quarter, registering a growth of 245.04% on YoY basis.

During the quarter, EBITDA grew 6% YoY to Rs 350 crore and EBITDA margin improved to 16% as against 17% posted in Q3 FY24.

On nine-month basis, the firm’s reported consolidated net loss of Rs 62.37 crore in 9M FY25 as against net loss of Rs 83.45 crore in 9M FY24.

Revenue from operations grew 13.85% YoY to Rs 6,397.11 crore during the nine period ended on 31 December 2024, primarily driven by high-teen growth in the CDMO business.

EBITDA grew by 20% YoY to Rs 977 crore for 9M FY25, supported by operating leverage, cost optimization initiatives and superior revenue mix.

The company's revenue from contract development and manufacturing organization (CDMO) was at Rs 3,659 crore (up 18% YoY), complex hospital generics (CHG) stood at Rs 1,928 crore (up 8% YoY) and India consumer healthcare (ICH) came in at Rs 819 crore (up 10% YoY) during the period under review.

Nandini Piramal, chairperson of Piramal Pharma, said, “FY25 so far has been a steady year for the Company with revenue growth of 14% and EBITDA growing at 20%. Our CDMO business continues to deliver robust performance with 18% revenue growth along with EBITDA margin improvement in 9MFY25. This performance was largely led by innovation related work.

Our CHG business registered an early-teen revenue growth during the quarter on the back of strong volume growth in our Inhalation Anesthesia portfolio. In our ICH business, power brands continue to register about 19% growth.

The quarter also marked a significant milestone in our journey towards sustainable manufacturing with the conversion of coal-fired steam boiler at our Digwal facility to operate on biomass briquettes. This will significantly reduce our GHG emissions - underscoring our unwavering commitment towards the planet.”

Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products.

The scrip added 1.67% to currently trade at Rs 222.60 on the BSE.

Powered by Capital Market - Live News

In a regulatory filing made after market hours yesterday, the pharmaceutical company stated that the US FDA had conducted a General GMP inspection at its Turbhe facility from 11th February 2025 to 17th February 2025.

On conclusion of the inspection, a Form-483 was issued with 6 observations. “Observations are largely around improvement of procedures and practices and not related to data integrity.

The company is preparing a detailed response to said observations, which will be submitted to agency within stipulated timelines,” Piramal Pharma said in a statement.

Piramal Pharma (PPL) is a part of the Piramal group of companies. The pharmaceutical product portfolio of the company can be categorised into contract development and manufacturing organisations (CDMO), complex hospital generics (critical care), and consumer healthcare (OTC).

Powered by Capital Market - Live News

Profit before tax stood at Rs 66.80 crore in the December 2024 quarter, registering a growth of 245.04% on YoY basis.

During the quarter, EBITDA grew 6% YoY to Rs 350 crore and EBITDA margin improved to 16% as against 17% posted in Q3 FY24.

On nine-month basis, the firm’s reported consolidated net loss of Rs 62.37 crore in 9M FY25 as against net loss of Rs 83.45 crore in 9M FY24.

Revenue from operations grew 13.85% YoY to Rs 6,397.11 crore during the nine period ended on 31 December 2024, primarily driven by high-teen growth in the CDMO business.

EBITDA grew by 20% YoY to Rs 977 crore for 9M FY25, supported by operating leverage, cost optimization initiatives and superior revenue mix.

The company's revenue from contract development and manufacturing organization (CDMO) was at Rs 3,659 crore (up 18% YoY), complex hospital generics (CHG) stood at Rs 1,928 crore (up 8% YoY) and India consumer healthcare (ICH) came in at Rs 819 crore (up 10% YoY) during the period under review.

Nandini Piramal, chairperson of Piramal Pharma, said, “FY25 so far has been a steady year for the Company with revenue growth of 14% and EBITDA growing at 20%. Our CDMO business continues to deliver robust performance with 18% revenue growth along with EBITDA margin improvement in 9MFY25. This performance was largely led by innovation related work.

Our CHG business registered an early-teen revenue growth during the quarter on the back of strong volume growth in our Inhalation Anesthesia portfolio. In our ICH business, power brands continue to register about 19% growth.

The quarter also marked a significant milestone in our journey towards sustainable manufacturing with the conversion of coal-fired steam boiler at our Digwal facility to operate on biomass briquettes. This will significantly reduce our GHG emissions - underscoring our unwavering commitment towards the planet.”

Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products.

The scrip added 1.67% to currently trade at Rs 222.60 on the BSE.

Powered by Capital Market - Live News

Net profit of Piramal Pharma declined 63.60% to Rs 3.68 crore in the quarter ended December 2024 as against Rs 10.11 crore during the previous quarter ended December 2023. Sales rose 12.54% to Rs 2204.22 crore in the quarter ended December 2024 as against Rs 1958.57 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News